Dear Customers,
Due to the peculiarities of the methodology for conducting the studies listed below, the term for their implementation is up to 14 calendar days:
· Hepatitis B, quantitative (qualitative) determination of virus DNA, PCR;
· Hepatitis C, quantitative (qualitative) determination of the virus in blood serum, PCR;
· HIV, quantitative (qualitative) determination of virus RNA, PCR.
Completion time – 14-30 calendar days:
· Determination of the genotype and mutations of resistance to hepatitis B virus nucleotide analogues by sequencing;
· Determination of the hepatitis C virus genotype by sequencing.
All other tests are carried out within 5 working days.
Registry phone number: +375 17 268 04 41
PRICE LIST FOR MEDICAL SERVICES
TO FOREIGN CITIZENS
(payment for services is made in Belarusian rubles, as of May 10, 2022)
No. in order |
Medical service name |
Price, Belarusian rubles |
---|---|---|
1. |
Determination of hormones and tumor markers by EIA |
|
1.1. |
Determination of anti-thyroid peroxidase antibodies concentration (Anti-TPO) |
24,34 |
1.2. |
Determination of free thyroxine (T4 free) concentration |
25,38 |
1.3. |
Determination of thyrotropin (TSH) concentration |
23,88 |
2. |
Immunological tests |
|
2.4. |
Determination of reactive oxygen production by blood neutrophils |
16,00 |
2.5. |
Determination of the main subpopulations of blood mononuclear cells (T- and B-lymphocytes, NK cells, T-helpers, T-cytotoxic, activated lymphocytes) |
55,00 |
2.6. |
Determination of the main and additional subpopulations of blood mononuclear cells (T- and B-lymphocytes, NK cells, T-helpers, T-cytotoxic, activated lymphocytes) |
92,00 |
2.7. |
Determination of blood T-cell subpopulations (naive T-cells, central memory T-cells, preterminally differentiated T-cells, terminally differentiated T-cells) |
37,00 |
3. |
Diagnosis of parasitic diseases |
|
3.1. |
Test on the intestinal group of parasitic diseases (ascariasis, difilllobothriasis, trichuriasis, opisthorchiasis, clonorchiasis, blastocytosis). Sorption method. |
38,22 |
3.2. |
Test on the intestinal group of parasitic diseases (hymenolepiasis, diphyllobothriasis, schistosomiasis, nanophyetosis, metagonimiasis, etc.). Precipitation method. |
37,04 |
3.3. |
Coprogram |
9,85 |
3.4. |
Determination of helminth eggs by the Kato method |
3,01 |
3.5. |
Detection of class IgG antibodies to toxocar antigens by EIA |
19,14 |
3.6. |
Detection of class IgM antibodies to opisthorchis antigens by EIA |
19,27 |
3.7. |
Detection of class IgG antibodies to opisthorchis antigens by EIA |
19,27 |
3.8. |
Detection of class IgM antibodies to trichinella antigens by EIA |
20,11 |
3.9. |
Detection of class IgG antibodies to trichinella antigens by EIA |
20,11 |
3.10. |
Detection of class IgG antibodies to echinococcus antigens by EIA |
20,32 |
3.11. |
Detection of classes IgA, IgM, and IgG antibodies to Giardia antigens by EIA |
19,69 |
3.12. |
Detection of class IgM antibodies to lamblia antigens by EIA |
20,07 |
3.13. |
Detection of class IgG antibodies to Ascaris lumbricoides antigens by EIA |
22,71 |
4. |
Diagnosis of tick-borne infections |
|
4.2. |
Detection of antigen of pathogen of Lyme borreliosis in ticks by IIFR |
12,07 |
4.4. |
Detection of classes IgM and IgG antibodies to pathogen of Lyme borreliosis by IIFR |
32,29 |
4.5. |
Detection of class IgM antibodies to pathogen of Lyme borreliosis by IIFR |
26,03 |
4.6. |
Detection of class IgG antibodies to pathogen of Lyme borreliosis by IIFR |
25,84 |
4.7. |
Detection of class IgG antibodies to pathogen of Lyme borreliosis by EIA |
20,66 |
4.8. |
Detection of class IgM antibodies to tick-borne encephalitis virus by EIA |
18,85 |
4.9. |
Detection of class IgG antibodies to tick-borne encephalitis virus by EIA |
18,85 |
4.10. |
Detection of class IgM antibodies to pathogen of Lyme borreliosis by EIA |
20,66 |
4.11. |
Identification of RNA/DNA of pathogens transmitted by ixodid ticks (tick-borne encephalitis virus, Lyme disease, anaplasmosis, ehrlichiosis) by PCR |
63,55 |
5. |
Diagnosis of intestinal infections |
|
5.1. |
Identification of DNA of pathogen of yerseniasis (Y. pseudotuberculosis and Y. enterocolitica) by real-time PCR |
33,80 |
5.7. |
Determination of RNA pathogens of acute intestinal viral infections by PCR: Noro/rota/adeno/entero |
58,16 |
5.8. |
Enterovirus antigen detection by EIA |
23,54 |
5.9. |
Detection of class IgM antibodies to enteroviruses by EIA |
19,37 |
5.11. |
Test of human stool material for the quantitative determination of calprotectin by EIA |
48,99 |
6. |
Diagnosis of gastrointestinal diseases |
|
6.2. |
Detection of total antibodies to CagA antigen Helicobacter pylori by EIA |
20,74 |
7. |
Diagnosis of vaccine preventable infections |
|
7.1. |
Determination of antibodies to poliovirus types 1, 2, and 3 in NT in cell culture |
46,65 |
7.2. |
Detection of class IgM antibodies to parvovirus В19 by EIA |
15,47 |
7.3. |
Detection of class IgG antibodies to parvovirus В19 by EIA |
13,26 |
7.4. |
Detection of parvovirus В19 DNA by real-time PCR |
13,07 |
7.5. |
Detection of class IgM antibodies to chickenpox virus by EIA |
12,70 |
7.6. |
Detection of class IgG antibodies to chickenpox virus by EIA |
11,30 |
7.7. |
Detection of class IgM antibodies to mumps virus by EIA |
15,95 |
7.8. |
Detection of class IgG antibodies to mumps virus by EIA |
14,85 |
7.9. |
Detection of class IgG antibodies to к вирусу краснухи by EIA |
13,13 |
7.10. |
Detection of class IgM antibodies to к вирусу краснухи by EIA |
14,77 |
7.11. |
Выявление возбудителя коклюша by PCR |
16,50 |
7.12. |
Detection of mumps virus RNA by RT-PCR |
17,54 |
7.13. |
Identification of Corynebacterium diphtheriae by PCR |
18,60 |
7.14. |
Detection of measles virus RNA by real-time RT-PCR |
25,27 |
7.15. |
Detection of measles virus by PCR |
25,27 |
7.16. |
Detection of class IgM antibodies to measles virus by EIA |
15,63 |
7.17. |
Detection of class IgG antibodies to measles virus by EIA |
13,66 |
7.18. |
Detection of class IgG antibodies to pertussis toxin by EIA |
14,86 |
7.19. |
Detection of class IgG antibodies to diphtheria toxin by EIA |
20,75 |
7.20. |
Detection of class IgG antibodies to tetanus toxoid by EIA |
19,41 |
8. |
Diagnosis of respiratory infections |
|
8.1. |
Detection of class IgM antibodies to Mycoplasma pneumonia by EIA |
20,32 |
8.2. |
Detection of class IgG antibodies to Mycoplasma pneumonia by EIA |
20,32 |
8.3. |
Detection of class IgG antibodies to Chlamydia pneumonia by EIA |
20,32 |
8.4. |
Detection of class IgM antibodies to Chlamydia pneumonia by EIA |
20,32 |
9. |
Diagnosis of polyomavirus |
|
9.1. |
Quantitation determination of polyomaviruses by PCR (BKV or JCV test) |
36,64 |
9.2. |
Qualitative detection of polyomaviruses by PCR (BKV or JCV test) |
33,10 |
10. |
Diagnosis of chlamydiosis |
|
10.1. |
Isolation of chlamydia (Ch. trachomatis) in cell culture with a cytopathic effect |
90,82 |
10.2. |
Isolation of chlamydia (Ch. trachomatis) in cell culture with a cytopathic effect, with determination of sensitivity to 6 antibiotics |
151,00 |
10.3. |
Detection of chlamydia (Ch. trachomatis) by IFR |
23,47 |
10.5. |
Determination of immunoglobulins of one class to Chlamydia trachomatis with manual calculation of the positivity coefficient and antibody titer |
4,61 |
10.6. |
Detection of Chlamydia trachomatis DNA by PCR |
18,24 |
10.7. |
Chlamydia detection using fluorescently labeled immunomagnetic nanoparticles |
29,94 |
11. |
Diagnosis of toxoplasmosis |
|
11.1. |
Detection of class IgG antibodies to Toxoplasma gondii by EIA |
23,27 |
11.2. |
Detection of class IgA antibodies to Toxoplasma gondii by EIA |
19,80 |
11.3. |
Detection of class IgM antibodies to Toxoplasma gondii by EIA |
18,22 |
12. |
Diagnosis of sexually transmitted infections |
|
12.1. |
Isolation of Trichomonas by seeding on cell culture |
90,22 |
12.2. |
Cultural study for ureaplasmas and mycoplasmas, semi-quantitative titer assessment and determination of sensitivity to antibiotics |
33,52 |
12.3. |
Detection of ureaplasma DNA (U. urealyticum, U. parvum) by PCR |
18,44 |
12.5. |
Detection of Trichomonas vaginalis DNA by PCR |
18,76 |
12.6. |
Detection of Gardnerella vaginalis DNA by PCR |
18,44 |
12.7. |
Microscopic examination of genitourinary organs discharge (from urethra, cervical canal, vagina, prostate secretion) |
16,47 |
12.12. |
Detection of Chlamydia trachomatis antigens by IFR |
23,34 |
12.13. |
Detection of Ureaplasma urealyticim antigens by IFR |
23,55 |
12.14. |
Detection of cytomegalovirus antigens by IIFR |
27,84 |
13. |
Diagnosis of papillomavirus infection |
|
13.1. |
Detection of DNA of human papillomavirus types 16 and 18 by PCR |
19,23 |
13.2. |
Quantitative detection of DNA of 21 types of human papillomavirus with PCR typing, HPV quantum 21 |
57,08 |
14. |
Diagnosis of a herpetic infection |
|
14.1. |
Isolation of herpes virus type 1 and 2, cytomegalovirus in cell culture |
97,96 |
14.2. |
Detection of herpes virus 1, 2 types by IIFR |
12,55 |
14.3. |
Detection of class IgG antibodies to herpes virus 6 type by EIA |
22,25 |
14.4. |
Detection of class IgM antibodies to herpes simplex virus 1 and 2 types by EIA |
18,22 |
14.5. |
Detection of class IgG antibodies to herpes simplex virus 1 and 2 types by EIA |
17,80 |
14.6. |
Detection of class IgM antibodies to cytomegalovirus by EIA |
18,22 |
14.7. |
Detection of class IgG antibodies to cytomegalovirus by EIA |
19,80 |
14.8. |
Detection of class IgG antibodies to nuclear antigen NA of Epstein-Barr virus by EIA |
20,28 |
14.9. |
Detection of class IgM antibodies to capsid antigen VCA of Epstein-Barr virus by EIA |
20,61 |
14.10. |
Detection of class IgG antibodies to early EA antigens of Epstein-Barr virus by EIA |
20,28 |
14.11. |
Detection of herpes virus type 6 DNA by PCR |
19,16 |
14.12. |
Detection of cytomegalovirus DNA by PCR |
18,55 |
14.13. |
Detection of Epstein-Barr virus DNA by PCR |
26,30 |
14.14. |
Detection of DNA of herpes simplex virus 1 and 2 types by PCR |
18,19 |
15. |
HIV diagnosis |
|
15.1. |
Determination of HIV subtype and mutations of resistance to antiretroviral drugs |
132,62 |
15.2. |
Determination of HIV subtype and phylogenetic relationships |
141,22 |
15.3. |
Quantitative determination of HIV RNA by PCR |
37,47 |
16. |
Diagnosis of hepatitis B |
|
16.1. |
Determination of the subtype and mutations of resistance to analogues of nucleotides of the hepatitis B virus by sequencing |
93,63 |
16.2. |
Determination of the subtype or mutations of resistance to analogues of nucleotides of the hepatitis B virus by sequencing |
93,63 |
16.3. |
Quantitative determination of hepatitis B virus DNA |
26,38 |
16.4. |
Hepatitis B marker detection (HBsAg) by EIA |
15,70 |
16.5. |
Hepatitis B marker detection (HBsAg) by EIA and a confirmatory test |
37,93 |
16.6. |
Confirmatory test to presence of HBsAg of the hepatitis B virus |
22,23 |
17. |
Diagnosis of hepatitis C |
|
17.1. |
Determination of the subtype of hepatitis C virus by sequencing |
94,41 |
17.2. |
Determination of the polymorphism of IL28B gene in the regions rs12979860 and rs8099917 by sequencing |
90,30 |
17.3. |
Detection of markers of hepatitis C (class IgM and IgG antibodies) by EIA |
12,72 |
17.4. |
Highly sensitive quantification of hepatitis C virus RNA by enrichment PCR |
52,07 |
17.5. |
Quantitative determination of hepatitis C virus RNA by PCR |
38,36 |
17.6. |
Confirmatory test to presence of class IgG and IgM antibodies to the hepatitis C virus |
26,40 |
17.7. |
Detection of markers of hepatitis C (class IgM and IgG antibodies) and a confirmatory test by EIA |
39,12 |
18. |
Diagnosis of COVID19 |
|
18.1. |
Detection of SARS-CoV-2 virus nucleocapsid antigen by express immunochromatographic analysis in a swab from the oropharynx and nasopharynx |
26,94 |
18.2. |
Test of nasopharyngeal swabs for Covid-19 by PCR |
43,00 |
|
Determination of antibodies to viral and bacterial agents by enzyme immunoassay with semi-automated calculation |
|
18.3. |
Detection of total antibodies to SARS-CoV-2 coronavirus (single test) |
50,78 |
18.4. |
Detection of total antibodies to SARS-CoV-2 coronavirus (one test in a series) |
23,48 |
18.5. |
Detection of class IgM antibodies to SARS-CoV-2 coronavirus (single test) |
48,23 |
18.6. |
Detection of class IgM antibodies to SARS-CoV-2 coronavirus (one test in a series) |
22,52 |
18.7. |
Detection of class IgG antibodies to SARS-CoV-2 coronavirus (single test) |
48,29 |
18.8. |
Detection of class IgG antibodies to SARS-CoV-2 coronavirus (one test in a series) |
22,54 |
18.9. |
Detection of class IgG antibodies to SARS-CoV-2 coronavirus after immunization with Sputnik V vaccine |
37,50 |
18.10. |
QR code design |
6,00 |
18.11. |
Quantitative determination of class IgG antibodies to SARS-CoV-2 coronavirus S-protein (single test) |
60,00 |
18.12. |
Quantitative determination of class IgG antibodies to SARS-CoV-2 coronavirus S-protein (one test in a series) |
28,00 |
19. |
Individual services |
|
19.1. |
Registration (preliminary and final) of the material, patient passport data, and test results in journals and forms |
1,23 |
19.2. |
Reception, preliminary registration of plasma or serum samples, or other ready-made biomaterials, accounting for the results issuance in centralized laboratories |
0,20 |
19.3. |
Pipetting with glass pipettes |
1,04 |
19.4. |
Pipetting with semi-automatic pipettes |
0,32 |
19.5. |
Treatment of venous blood to obtain plasma or serum |
0,33 |
19.6. |
Finger blood sampling |
2,23 |
19.7. |
Blood sampling from a vein |
4,01 |
19.8. |
Blood sampling from a vein for antibodies to SARS CoV-2 |
4,87 |
19.9. |
Taking a smear for test |
2,19 |
19.10. |
Taking a nasopharyngeal swab for Covid 19 |
3,19 |
19.11. |
Sampling of bacteriological material from patients into the transport medium (from discharge of nose, pharynx, skin foci of inflammation, eyes), each separately |
3,38 |
19.12. |
Sampling of bacteriological material from patients (from discharge of nose, pharynx, skin foci of inflammation, eyes), each separately |
2,00 |
19.13. |
Preparation of transport medium with mucolytic for PCR |
1,14 |
19.14. |
Biological material sampling |
3,19 |
19.15. |
Taking gynecological smear for bacterial culture (women) |
3,94 |
19.16. |
Taking urological smear for bacterial culture (men) |
2,59 |
19.17. |
Taking gynecological smear (women) |
3,56 |
19.18. |
Taking urological smear (men) |
1,95 |
20. |
Electron microscopy |
|
20.1. |
Sample preparation and its electron microscope examination |
250,33 |
20.2. |
Electron microscopic analysis of ultrathin sections |
102,36 |
21. |
Diagnostic bacteriological examination |
|
21.1. |
Bacteriological examination of sputum and bronchial washings for aerobic and facultative microorganisms |
28,81 |
21.2. |
Bacteriological examination of urine for aerobic and facultative microorganisms |
23,10 |
21.3. |
Bacteriological examination of pus, wound discharge, infiltrates, abscesses, transudates, exudates for aerobic and facultative microorganisms |
28,51 |
21.4. |
Bacteriological examination of the discharge of the genital organs |
30,59 |
21.5. |
Bacteriological examination of detachable eyes for anaerobic and facultative anaerobic microorganisms |
26,16 |
21.6. |
Bacteriological examination of the discharge of the nasopharynx, nose, ear for anaerobic and facultative anaerobic microorganisms |
21,72 |
21.7. |
Bacteriological examination of breast milk anaerobic and facultative anaerobic microorganisms |
16,97 |
21.8. |
Bacteriological examination for diphtheria of the detachable pharynx and nose |
11,05 |
21.9. |
Bacteriological examination of feces for pathogenic intestinal flora |
16,89 |
21.10. |
Bacteriological study of intestinal microbiocinosis (dysbacteriosis) |
50,35 |
21.11. |
Bacteriological examination of feces for pathogenic intestinal flora with serodiagnosis |
55,69 |
22. |
Molecular biological research |
|
22.1. |
Primary processing of other biological material |
6,00 |
22.2. |
Isolation of RNA/DNA from other biological material (sorbent method) (single) |
16,30 |
22.3. |
Isolation of RNA/DNA from other biological material (sorbent method) (serial) |
8,20 |
22.4. |
Real-time PCR with detection by endpoint for qualitative DNA/RNA detection (single) |
14,00 |
22.5. |
Real-time PCR with detection by endpoint for qualitative DNA/RNA detection (serial) |
10,40 |
Notes:
Ag – antigen
EIA – enzyme immunoassay
IIFR – indirect immunofluorescence reaction
IFR – immunofluorescence reaction
NT – neutralization testing
PCR – polymerase chain reaction
RT-PCR – reverse transcription PCR